Literature DB >> 28238021

The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma.

Constantin Lapa1, Andreas Schirbel2, Samuel Samnick2, Katharina Lückerath2, K Martin Kortüm3, Stefan Knop3, Hans-Jürgen Wester4, Andreas K Buck2, Martin Schreder3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28238021     DOI： 10.1007/s00259-017-3656-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.

Authors:  Yuji Nakamoto; Kensuke Kurihara; Masatoshi Nishizawa; Kouhei Yamashita; Koya Nakatani; Tadakazu Kondo; Akifumi Takaori-Kondo; Kaori Togashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

2.  In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Authors:  Kathrin Philipp-Abbrederis; Ken Herrmann; Stefan Knop; Margret Schottelius; Matthias Eiber; Katharina Lückerath; Elke Pietschmann; Stefan Habringer; Carlos Gerngroß; Katharina Franke; Martina Rudelius; Andreas Schirbel; Constantin Lapa; Kristina Schwamborn; Sabine Steidle; Elena Hartmann; Andreas Rosenwald; Saskia Kropf; Ambros J Beer; Christian Peschel; Hermann Einsele; Andreas K Buck; Markus Schwaiger; Katharina Götze; Hans-Jürgen Wester; Ulrich Keller
Journal:  EMBO Mol Med       Date:  2015-04       Impact factor: 12.137

3.  11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.

Authors:  Constantin Lapa; Stefan Knop; Martin Schreder; Martina Rudelius; Markus Knott; Gerhard Jörg; Samuel Samnick; Ken Herrmann; Andreas K Buck; Hermann Einsele; Katharina Lückerath
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

4.  11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.

Authors:  Cristina Nanni; Elena Zamagni; Michele Cavo; Domenico Rubello; Paola Tacchetti; Cinzia Pettinato; Mohsen Farsad; Paolo Castellucci; Valentina Ambrosini; Gian Carlo Montini; Adil Al-Nahhas; Roberto Franchi; Stefano Fanti
Journal:  World J Surg Oncol       Date:  2007-06-20       Impact factor: 2.754

5.  11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.

Authors:  Katharina Lückerath; Constantin Lapa; Christa Albert; Ken Herrmann; Gerhard Jörg; Samuel Samnick; Herrmann Einsele; Stefan Knop; Andreas K Buck
Journal:  Oncotarget       Date:  2015-04-10
  5 in total
  4 in total

1.  11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.

Authors:  Constantin Lapa; Maria J Garcia-Velloso; Katharina Lückerath; Samuel Samnick; Martin Schreder; Paula Rodriguez Otero; Jan-Stefan Schmid; Ken Herrmann; Stefan Knop; Andreas K Buck; Hermann Einsele; Jesus San-Miguel; Klaus Martin Kortüm
Journal:  Theranostics       Date:  2017-07-23       Impact factor: 11.556

Review 2.  The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

Authors:  Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

Review 3.  In Vivo Targeting of CXCR4-New Horizons.

Authors:  Margret Schottelius; Ken Herrmann; Constantin Lapa
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

Review 4.  CXCR4-directed theranostics in oncology and inflammation.

Authors:  Malte Kircher; Peter Herhaus; Margret Schottelius; Andreas K Buck; Rudolf A Werner; Hans-Jürgen Wester; Ulrich Keller; Constantin Lapa
Journal:  Ann Nucl Med       Date:  2018-08-13       Impact factor: 2.668
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.